Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

United States Preventive Services Task Force screening mammography recommendations: science ignored.

Hendrick RE, Helvie MA.

AJR Am J Roentgenol. 2011 Feb;196(2):W112-6. doi: 10.2214/AJR.10.5609.

PMID:
21257850
2.

Screening for Breast Cancer: Systematic Evidence Review Update for the US Preventive Services Task Force [Internet].

Nelson HD, Tyne K, Naik A, Bougatsos C, Chan B, Nygren P, Humphrey L.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2009 Nov.

3.

The 2009 U.S. Preventive Services Task Force guidelines ignore important scientific evidence and should be revised or withdrawn.

Kopans DB.

Radiology. 2010 Jul;256(1):15-20. doi: 10.1148/radiol.10100057. No abstract available.

PMID:
20574081
4.

When evidence collides with anecdote, politics, and emotion: breast cancer screening.

[No authors listed]

Ann Intern Med. 2010 Apr 20;152(8):531-2. doi: 10.7326/0003-4819-152-8-201004200-00210. Epub 2010 Feb 15. No abstract available.

PMID:
20157099
5.

Mammography screening for breast cancer: a view from 2 worlds.

Murphy AM.

JAMA. 2010 Jan 13;303(2):166-7. doi: 10.1001/jama.2009.1991. No abstract available.

PMID:
20068212
6.

The benefits and harms of mammography screening: understanding the trade-offs.

Woloshin S, Schwartz LM.

JAMA. 2010 Jan 13;303(2):164-5. doi: 10.1001/jama.2009.2007. No abstract available.

PMID:
20068211
7.

The 2009 breast cancer screening recommendations of the US Preventive Services Task Force.

Woolf SH.

JAMA. 2010 Jan 13;303(2):162-3. doi: 10.1001/jama.2009.1989. No abstract available.

PMID:
20068210
8.

Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms.

Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, Huang H, Lee SJ, Munsell M, Plevritis SK, Ravdin P, Schechter CB, Sigal B, Stoto MA, Stout NK, van Ravesteyn NT, Venier J, Zelen M, Feuer EJ; Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network.

Ann Intern Med. 2009 Nov 17;151(10):738-47. doi: 10.7326/0003-4819-151-10-200911170-00010. Erratum in: Ann Intern Med. 2010 Jan 19;152(2):136.

9.

Quality of life valuations of mammography screening.

Bonomi AE, Boudreau DM, Fishman PA, Ludman E, Mohelnitzky A, Cannon EA, Seger D.

Qual Life Res. 2008 Jun;17(5):801-14. doi: 10.1007/s11136-008-9353-2. Epub 2008 May 20.

PMID:
18491217
10.

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, Goldhirsch A, Gray R, Peto R, Pritchard KI, Wood WC.

Lancet. 2008 Jan 5;371(9606):29-40. doi: 10.1016/S0140-6736(08)60069-0. Review.

PMID:
18177773
11.

Mammography surveillance and mortality in older breast cancer survivors.

Lash TL, Fox MP, Buist DS, Wei F, Field TS, Frost FJ, Geiger AM, Quinn VP, Yood MU, Silliman RA.

J Clin Oncol. 2007 Jul 20;25(21):3001-6. Epub 2007 Jun 4.

PMID:
17548838
12.

Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care.

El-Tamer MB, Ward BM, Schifftner T, Neumayer L, Khuri S, Henderson W.

Ann Surg. 2007 May;245(5):665-71.

13.

The decrease in breast-cancer incidence in 2003 in the United States.

Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA.

N Engl J Med. 2007 Apr 19;356(16):1670-4.

14.

Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial.

Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L; Trial Management Group.

Lancet. 2006 Dec 9;368(9552):2053-60.

PMID:
17161727
15.
16.

A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends.

Clarke LD, Plevritis SK, Boer R, Cronin KA, Feuer EJ.

J Natl Cancer Inst Monogr. 2006;(36):96-105. Review.

PMID:
17032899
17.

A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000.

Plevritis SK, Sigal BM, Salzman P, Rosenberg J, Glynn P.

J Natl Cancer Inst Monogr. 2006;(36):86-95.

PMID:
17032898
18.

A stochastic model for predicting the mortality of breast cancer.

Lee S, Zelen M.

J Natl Cancer Inst Monogr. 2006;(36):79-86.

PMID:
17032897
19.

The MISCAN-Fadia continuous tumor growth model for breast cancer.

Tan SY, van Oortmarssen GJ, de Koning HJ, Boer R, Habbema JD.

J Natl Cancer Inst Monogr. 2006;(36):56-65.

PMID:
17032895
20.

Supplemental Content

Support Center